  |
|
The company also today announced a strategic reprioritization and reallocation of resources within its distribution, research and development and clinical programs to focus on areas of strong projected growth in FFR (Fractional Flow Reserve), peripheral applications, coronary IVUS (Intravascular Imaging) driven by the ADAPT-DES clinical data and Axsun Medical. This has resulted in a corporate restructuring charge that reflects the discontinuation of certain product development programs effective September 30, 2013. For the quarter ended September 30, 2013, Volcano reported revenues of $95.8 million versus revenues of $93.7 million in the same period a year ago. On a constant currency basis, revenues increased eight percent year-over-year after adjusting for a negative impact of approximately $5.4 million from foreign currency. Medical segment revenues increased approximately three and nine percent on a reported and constant currency basis, respectively. The company reported a net loss on a GAAP basis of $8.5 million, or $0.15 per share, in the third quarter of 2013, versus net income of $2.0 million, or $0.04 per diluted share, in the same period a year ago. The results for the third quarter of 2013 included non-cash restructuring charges for the impairment of intangible assets of $4.6 million, acquisition-related expenses of $1.3 million and net interest expense of $6.4 million versus $1.6 million a year ago, reflecting the company's convertible debt offering completed in the fourth quarter of 2012. Excluding acquisition-related items, amortization of intangibles and non-cash interest expense on convertible notes, net of tax, the company reported a non-GAAP loss of $0.08 per share. For the first nine months of 2013, Volcano reported revenues of $290.4 million versus $279.4 million a year ago. This represents an increase of four percent on a reported basis versus the same period a year ago and nine percent on a constant currency basis after adjusting for a $15.1 million negative effect from foreign currency. Medical segment revenues increased five and ten percent on a reported and constant currency basis, respectively. The company reported a net loss on a GAAP basis of $14.0 million, or $0.26 per share, for the first nine months of 2013, versus net income on a GAAP basis of $5.5 million, or $0.10 per diluted share, in the same period a year ago. The results for the first nine months of 2013 include net interest expense of $18.9 million versus $4.3 million a year ago. In addition, the company recorded an expense of $3.7 million related to acquisitions and a gain of $4.1 million related to the sale of a strategic investment, as well as the restructuring charge recorded in the third quarter of 2013. The company also recorded an exchange rate loss of $1.0 million in the first nine months of 2013 versus $319,000 in the same period a year ago. Excluding acquisition-related items, amortization of intangibles and non-cash interest expenses on convertible notes, net of tax, the company reported a non-GAAP net loss per share of $0.03.
"Overall, our business experienced solid growth. Growth drivers included a seven percent increase in our U.S. IVUS revenues, due in great part to a roughly 30 percent increase in peripheral revenues versus the third quarter a year ago, as well as a 27 percent increase in combined revenues in Europe," said Scott Huennekens, president and chief executive officer. "At the same time, our U.S. coronary IVUS revenues were impacted by the continued decline in PCI volumes, although we are beginning to see some stabilization in activity. Also, despite the growth in our FFR business in Japan, revenues were not to our expectations," he added. "We are finishing 2013 with strong momentum in our market expansion and product development programs. In addition to our growth in the peripheral market and revenues from the sale of the PioneerPlus™ Re-Entry catheter that we acquired during the quarter, we have initiated a limited market release for our Crux® inferior vena cava (IVC) filter and the full market release of our Verrata™ everyday pressure wire," Huennekens noted. "Volcano also had a very strong showing at the recent Transcatheter Cardiovascular Therapeutics (TCT) conference. Data from our ADAPT DES study demonstrated the use of IVUS in stent patients changed the procedure 74 percent of the time and was associated with reductions in serious patient events, including stent thrombosis and myocardial infarction, as well as target lesion revascularizations—particularly for patients with more complex lesions. Additionally, the full results from our ADVISE II study showed that a hybrid iFR® (Instant Wave-Free Ratio) approach correctly matched an FFR-only approach in more than 94 percent of coronary stenoses and successfully avoided usage of adenosine in 65 percent of patients, reflecting findings from earlier studies in the use of our iFR technology," he said. The strategic reprioritization program announced today is designed to enhance the allocation of resources and improve operating predictability and results. Key elements of the initiative include the discontinuation of development programs for the company's Forward-Looking IVUS, Forward-Looking Intra-Cardiac Echo and Optical Coherence Tomography intravascular imaging products. The operating expenses associated with these three discontinued programs were approximately $12.0 million annually. In addition to the restructuring charge recorded in the third quarter of 2013, the company expects to record a restructuring charge of up to $15.0 million, including up to $7.0-$7.5 million in cash charges, in the fourth quarter of 2013. "We will be reinvesting the savings from this reprioritization of resources in higher growth, lower risk revenue generating product and market development opportunities. These include peripheral, FFR and expanded distribution. We believe this reprioritization initiative better focuses and positions Volcano to compete more effectively in our growth markets," Huennekens said. "The opportunities that will be contributing revenues in 2014 include the expanded distribution in the peripheral market and the commercialization of our new offerings, including our Crux IVC filter, the Sync-Rx platform technology, PioneerPlus and Verrata. In addition, we expect to drive further penetration of our iFR offering in Japan and Europe, and anticipate regulatory approval and commercial launch of iFR in the U.S. in the second half of 2014," Huennekens noted. Guidance The company also provided updated guidance and now expects gross margins on a reported basis will be in the range of 64.0-65.0 percent and that operating expense, including restructuring charges, will be 71.0-72.0 percent of revenues. On a reported basis, the company expects a GAAP net loss of $0.56-$0.58 per share and a non-GAAP net loss of $0.25-$0.27 per share. Non-GAAP results exclude acquisition-related expenses, amortization of intangibles and non-cash interest expense, and assume an effective tax rate of 38.0 percent for the GAAP to non-GAAP adjustments. The impact of restructuring charges in 2013 will be up $0.21 per share on both a GAAP and non-GAAP basis. The company expects weighted average basic shares in 2013 will be approximately 54.6 million shares and approximately 56.2 million shares on a diluted basis. The company confirmed preliminary revenue guidance for 2014 as provided on October 28, 2013. It expects revenues will increase year-over-year in the range of nine-to-11 percent on a reported basis and eight-to-ten percent on a constant currency basis. Its outlook for 2014 reflects several factors, including an expectation that PCI's will be down approximately 2.5 percent in the U.S., two percent in Japan and flat in Europe year-over-year, and the anticipation of a reimbursement reduction of approximately 7.5 percent for all of its disposable products in Japan, beginning in the second quarter of the year. Conference Call Information About Volcano Note Regarding the Use of Non-GAAP Financial Measures Constant Currency Basis Revenue Changes: Volcano reports changes in revenues on a constant currency basis, which is a non-GAAP financial measure. Volcano believes that investors' understanding of the company's short-term and long-term financial results is enhanced by taking into consideration the impact of foreign currency translation on revenue. In addition, Volcano's management uses results of operations before currency translation to evaluate the operational performance of Volcano and as a basis for strategic planning. Volcano reports its expectations of earnings per share performance for excluding certain expenses described below; for additional details please see the "Reconciliation of GAAP to non-GAAP EPS Guidance" table in this press release. This accompanying table has more details on the GAAP financial measures that are most directly comparable to non-GAAP financial measures and the related reconciliations between these financial measures. Exclusion of Acquisition-Related Expenses: Volcano excludes acquisition-related expenses because it does not considerer these acquisition-related costs and adjustments to be related to the continuing organic operations of the acquired businesses and are generally not relevant to assessing or estimating the long-term performance of the acquired assets. In addition, the size, complexity and/or volume of past acquisitions, which often drive the magnitude of acquisition-related costs, may not be indicative of the size, complexity and/or volume of future acquisitions. Exclusion of Amortization of Intangibles: Volcano excludes amortization of intangibles because it is a non-cash expense relating primarily to acquisitions. At the time of an acquisition, the intangible assets of the acquired company, which consist of technology and supplier agreements, are valued and amortized over their estimated lives. Volcano believes that since intangible assets represent efforts of the acquired company to build value prior to acquisition, Volcano management eliminates the impact of the amortization when evaluating its current operating performance. Exclusion of Non-Cash Interest Expenses: In addition to disclosing the financial statement impact of the authoritative guidance for convertible debt accounting, Volcano management believes that excluding the impact of this authoritative guidance because it is non-cash in nature, may provide meaningful supplemental information regarding elements of the company's borrowing costs in order to properly understand its operational performance and liquidity, and facilitates comparisons to competitors' results. Forward-Looking Statements Source: Volcano Corporation |
